% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Schemmert:894084,
      author       = {Schemmert, Sarah and Camargo, Luana Cristina and Honold,
                      Dominik and Gering, Ian and Kutzsche, Janine and Willuweit,
                      Antje and Willbold, Dieter},
      title        = {{I}n {V}itro and {I}n {V}ivo {E}fficacies of the {L}inear
                      and the {C}yclic {V}ersion of an {A}ll-d-{E}nantiomeric
                      {P}eptide {D}eveloped for the {T}reatment of {A}lzheimer’s
                      {D}isease},
      journal      = {International journal of molecular sciences},
      volume       = {22},
      number       = {12},
      issn         = {1422-0067},
      address      = {Basel},
      publisher    = {Molecular Diversity Preservation International},
      reportid     = {FZJ-2021-03030},
      pages        = {6553 -},
      year         = {2021},
      abstract     = {Multiple sources of evidence suggest that soluble amyloid
                      β (Aβ)-oligomers are responsible for the development and
                      progression of Alzheimer’s disease (AD). In order to
                      specifically eliminate these toxic Aβ-oligomers, our group
                      has developed a variety of all-d-peptides over the past
                      years. One of them, RD2, has been intensively studied and
                      showed such convincing in vitro and in vivo properties that
                      it is currently in clinical trials. In order to further
                      optimize the compounds and to elucidate the characteristics
                      of therapeutic d-peptides, several rational drug design
                      approaches have been performed. Two of these d-peptides are
                      the linear tandem (head-to-tail) d-peptide RD2D3 and its
                      cyclized form cRD2D3. Tandemization and cyclization should
                      result in an increased in vitro potency and increase
                      pharmacokinetic properties, especially crossing the
                      blood–brain-barrier. In comparison, cRD2D3 showed a
                      superior pharmacokinetic profile to RD2D3. This fact
                      suggests that higher efficacy can be achieved in vivo at
                      equally administered concentrations. To prove this
                      hypothesis, we first established the in vitro profile of
                      both d-peptides here. Subsequently, we performed an
                      intraperitoneal treatment study. This study failed to
                      provide evidence that cRD2D3 is superior to RD2D3 in vivo as
                      in some tests cRD2D3 failed to show equal or higher
                      efficacy.},
      cin          = {IBI-7 / INM-4},
      ddc          = {540},
      cid          = {I:(DE-Juel1)IBI-7-20200312 / I:(DE-Juel1)INM-4-20090406},
      pnm          = {323 - Molecular Targets $\&$ Therapies (POF4-323) / 5244 -
                      Information Processing in Neuronal Networks (POF4-524)},
      pid          = {G:(DE-HGF)POF4-323 / G:(DE-HGF)POF4-5244},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {34207233},
      UT           = {WOS:000665922100001},
      doi          = {10.3390/ijms22126553},
      url          = {https://juser.fz-juelich.de/record/894084},
}